ArticleNature2020
Integrating genomic features for non-invasive early lung cancer detection.
Open access · greenAbstract readValidation Study
In one paragraph
Article in Nature, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 398 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
398citing papers in PubMed, 3 pooled it
34.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
398 citing papers in PubMed, 3 syntheses or guidelines pooled it, 667 citations in OpenAlex.
- Blood-Based Circulating Tumor DNA Assays for Early Colorectal Cancer Detection: A Systematic Review of Performance in Asymptomatic Screening Populations.International journal of cancer · 2026Pooled it
- Innovative technologies and their clinical prospects for early lung cancer screening.Clinical and experimental medicine · 2025Pooled it
- Pooled it
- Tumor-Informed ctDNA in Guiding First-Line Immunochemotherapy in Advanced Non-Small Cell Lung Cancers.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Trial
- Analysis of Circulating Tumor DNA Predicts Outcomes of Short-Course Consolidation Immunotherapy in Unresectable Stage III NSCLC.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2024Trial
- Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial.Nature medicine · 2024Trial
- Pulmonary nodules: classification, biomarkers, signaling pathways, diseases, early diagnosis and management.Signal transduction and targeted therapy · 2026Review
- Micro/Nanostructured Materials and Microfluidic Diagnostic Platforms Enable Multimodal Detection of Circulating Tumor Cells.Exploration (Beijing, China) · 2026Review
- Urine cell-free RNA for bladder cancer detection and treatment response prediction.Nature medicine · 2026Article
- Liquid Biopsy in Hematologic Malignancies: Advances, Challenges, and Future Directions.Asia-Pacific journal of clinical oncology · 2026Review
- Review
- Advancing the applications of liquid biopsies in oncology.Nature reviews. Genetics · 2026Review
- Circulating tumor DNA-based minimal residual disease-guided adjuvant therapy in solid tumors: Current evidence, clinical trial frameworks, and future directions.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2026Article
- Molecular Residual Disease in Non-Small Cell Lung Cancer: Technology or Patient Outcomes?Journal of personalized medicine · 2026Review
- Multifeature sequencing-based liquid biopsy for cancer diagnosis and monitoring.Genome medicine · 2026Review
- Interpretable deep learning model of circulating genomics for quantitative survival prediction in advanced non-small cell lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- DNAviWEB: sequencing-free clinical screening of liquid biopsies.Nucleic acids research · 2026Article
- A scalable deep-learning framework for cancer detection using cell-free DNA shallow whole-genome sequencing.Science advances · 2026Article
- Article
- Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results.Cancer discovery · 2026Article
338 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
48 authors at 11 institutions in 2 countries.
Jacob J Chabon *Stanford Cancer Institute, Stanford University, Stanford, CA, USA.
Emily G Hamilton *Program in Cancer Biology, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0001-7955-6244
David M Kurtz *Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-6382-4651
Mohammad S Esfahani *Stanford Cancer Institute, Stanford University, Stanford, CA, USA.
Everett J ModingStanford Cancer Institute, Stanford University, Stanford, CA, USA.
Henning StehrDepartment of Pathology, Stanford University, Stanford, CA, USA.
Joseph Schroers-MartinDivision of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA.
Barzin Y NabetStanford Cancer Institute, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-4824-3533
Binbin ChenDivision of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-2973-2718
Aadel A ChaudhuriDepartment of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0003-3115-3061
Chih Long LiuDivision of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA.
Angela B HuiStanford Cancer Institute, Stanford University, Stanford, CA, USA.
Michael C JinDivision of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA.
Tej D AzadDivision of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA.
Diego AlmanzaProgram in Cancer Biology, Stanford University, Stanford, CA, USA.
Young-Jun JeonStanford Cancer Institute, Stanford University, Stanford, CA, USA.
Monica C NesselbushProgram in Cancer Biology, Stanford University, Stanford, CA, USA.
Lyron Co Ting KehStanford Cancer Institute, Stanford University, Stanford, CA, USA.
Rene F BonillaDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA.
Christopher H YooDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-2132-8956
Ryan B KoDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-2123-9702
Emily L ChenDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA.
David J MerriottDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA.
Pierre P MassionDivision of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Aaron S MansfieldDepartment of Oncology, Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-9483-6903
Jin JenDivision of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Hong Z RenDivision of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Steven H LinDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Christina L CostantinoMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-4525-3533
Risa BurrMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Robert TibshiraniDepartment of Statistics, Stanford University, Stanford, CA, USA.
Sanjiv S GambhirDepartment of Bioengineering, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-2711-7554
Gerald J BerryDepartment of Pathology, Stanford University, Stanford, CA, USA.
Kristin C JensenDepartment of Pathology, Stanford University, Stanford, CA, USA.
Robert B WestDepartment of Pathology, Stanford University, Stanford, CA, USA.
Joel W NealDivision of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA.
Heather A WakeleeDivision of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA.
Billy W LooDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-2521-0544
Christian A KunderDepartment of Pathology, Stanford University, Stanford, CA, USA.
Ann N LeungDepartment of Radiology, Stanford University, Stanford, CA, USA.
Natalie S LuiDivision of Thoracic Surgery, Department of Cardiothoracic Surgery, Stanford University, Stanford, CA, USA.
Mark F BerryDivision of Thoracic Surgery, Department of Cardiothoracic Surgery, Stanford University, Stanford, CA, USA.
Joseph B ShragerVA Palo Alto Healthcare System, Palo Alto, Stanford, CA, USA.
Viswam S NairDepartment of Radiology, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0001-6376-8154
Daniel A HaberMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Lecia V SequistMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-8965-6991
Ash A AlizadehStanford Cancer Institute, Stanford University, Stanford, CA, USA. arasha@stanford.edu.ORCID http://orcid.org/0000-0002-5153-5625
Maximilian DiehnStanford Cancer Institute, Stanford University, Stanford, CA, USA. diehn@stanford.edu.ORCID http://orcid.org/0000-0003-2032-0581
Stanford University · USMayo Clinic in Arizona · USCalifornia Institute for Regenerative Medicine · USHarvard University · USHoward Hughes Medical Institute · USVA Palo Alto Health Care System · USInstitute for Stem Cell Biology and Regenerative Medicine · INThe University of Texas MD Anderson Cancer Center · USUniversity of Washington · USVA Tennessee Valley Healthcare System · USWashington University in St. Louis · US
Funding
Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3MPaul Calabresi Program in Clinical/Translational Research at Mayo ClinicK12CA090628 · NCI · MAYO CLINIC ROCHESTER · PI WEROHA, SARAVUT · 2001 to 2025
$19.7MLeveraging innovative technologies in basic and clinical cancer researchT32CA009302 · NCI · STANFORD UNIVERSITY · PI LAURA D ATTARDI, Aaron M Newman · 1985 to 2026
$19.1MCellular, molecular and quantitative imaging analysis of screening-detected lung adenocarcinomaU01CA196405 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MALDONADO, FABIEN · 2015 to 2020
$5.4MA Genomic Framework for Molecular Risk Prediction & Individualized Lymphoma TherapyR01CA233975 · NCI · STANFORD UNIVERSITY · PI ALIZADEH, ASH ARASH, DIEHN, MAXIMILIAN · 2019 to 2023
$2.8MDeveloping a genomic approach for cancer screeningDP2CA186569 · NCI · STANFORD UNIVERSITY · PI DIEHN, MAXIMILIAN · 2013 to 2013
$2.4MCancer Systems Biology Scholars ProgramR25CA180993 · NCI · STANFORD UNIVERSITY · PI PLEVRITIS, SYLVIA KATINA · 2014 to 2018
$2.2MPostdoctoral Training in the Radiation ScincesT32CA121940 · NCI · STANFORD UNIVERSITY · PI GRAVES, EDWARD E. · 2007 to 2018
$2.1MNoninvasive monitoring of lung cancer patients treated with radiotherapyR01CA188298 · NCI · STANFORD UNIVERSITY · PI ALIZADEH, ASH ARASH, DIEHN, MAXIMILIAN · 2015 to 2019
$1.8MMolecular Characterization and Personalized Approaches to Non-Hodgkin Lymphoma from Circulating Tumor DNAK08CA241076 · NCI · STANFORD UNIVERSITY · PI KURTZ, DAVID MATTHEW · 2019 to 2023
$957kNCI NIH HHS 1-K08-CA241076-01NCI NIH HHS DP2 CA186569NCI NIH HHS K08 CA241076NCI NIH HHS K12 CA090628NCI NIH HHS P30 CA015083NCI NIH HHS P30 CA015083-44S1NCI NIH HHS R01 CA188298NCI NIH HHS R01 CA233975NCI NIH HHS R25 CA180993NCI NIH HHS T32 CA009302NCI NIH HHS T32 CA121940NCI NIH HHS U01 CA196405
Abstract
Radiologic screening of high-risk adults reduces lung-cancer-related mortality
Indexed as
MutationCirculating Tumor DNACohort StudiesEarly Detection of CancerFemaleGenome, HumanHematopoiesisHumansLungLung NeoplasmsMaleMiddle AgedReproducibility of ResultsCirculating Tumor DNA
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.